Developmental Funds provide critical support to build research capacity aligned with strategic initiatives. Funds are requested to partially support two key initiatives: 1) recruitment of outstanding investigators to Huntsman Cancer Institute (HCI) ($200,000 per year) and 2) development of our translational research portfolio ($100,000 per year), via the following: Faculty Recruitment: Our five research Programs continue to identify areas of particular opportunity that align with the broad strategic objectives of the Cancer Center. We anticipate that the Cancer Center will spearhead recruitment of approximately 30 new members in the coming five-year period, with particular focus on high-priority areas that have emerged from our strategic planning. These include cancer genetics and epigenetics, cell migration and tumor metastasis, molecular imaging, investigational therapeutics, cancer prevention, epidemiology, behavioral research, and cancer outcomes, including research related to health disparities and survivorship. New recruitment will advance the missions of each of our Programs, with the greatest growth anticipated in our two newest Programs?Imaging, Diagnostics, and Therapeutics and Cancer Control and Population Sciences?with at least five recruits each. In addition, a major commitment is in place to recruit new leadership for the Divisions of Hematology and Oncology and to expand both Divisions via recruitment of cancer-focused, research-active faculty whose interests align with the abovementioned Cancer Center goals. We plan 14 new cancer-focused faculty recruitments in partnership with these two units during the next five years. These new faculty will be aligned with Cancer Center Programs based on their research interests. We request developmental funds in the amount of $200,000 per year to provide partial support ($50,000 per person) for four newly recruited investigators per year during their initial startup period. Translational Research: We have developed an effective strategy to promote translational research in our Center through the Director's Translational Research Initiative (DTRI). This initiative provides support for promising collaborative projects between basic scientists (including laboratory and population researchers) and clinical investigators. The goal is to stimulate productive transdisciplinary research with near-term clinical application. We request $100,000 per year for the partial support of this mechanism. Total annual support requested from the CCSG for developmental activities is $300,000. This amount will be complemented by HCI discretionary funds and other institutional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-24
Application #
8465107
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
24
Fiscal Year
2013
Total Cost
$204,655
Indirect Cost
$21,836
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Flores, Kristina G; Steffen, Laurie E; McLouth, Christopher J et al. (2016) Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families. J Genet Couns :
Khorashad, J S; Tantravahi, S K; Yan, D et al. (2016) Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia 30:2275-2279
(2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 53:800-811
Neklason, Deborah W; VanDerslice, James; Curtin, Karen et al. (2016) Evidence for a heritable contribution to neuroendocrine tumors of the small intestine. Endocr Relat Cancer 23:93-100
Norton, Maria C; Fauth, Elizabeth; Clark, Christine J et al. (2016) Family member deaths across adulthood predict Alzheimer's disease risk: The Cache County Study. Int J Geriatr Psychiatry 31:256-63
Piccolo, Stephen R; Hoffman, Laura M; Conner, Thomas et al. (2016) Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol 12:860
Zhu, Judy; Fleming, Aaron M; Orendt, Anita M et al. (2016) pH-Dependent Equilibrium between 5-Guanidinohydantoin and Iminoallantoin Affects Nucleotide Insertion Opposite the DNA Lesion. J Org Chem 81:351-9
Riedl, Jan; Fleming, Aaron M; Burrows, Cynthia J (2016) Sequencing of DNA Lesions Facilitated by Site-Specific Excision via Base Excision Repair DNA Glycosylases Yielding Ligatable Gaps. J Am Chem Soc 138:491-4
Serpico, Victoria; Liepert, Amy E; Boucher, Kenneth et al. (2016) The Effect of Previsit Education in Breast Cancer Patients: A Study of a Shared-decision-making Tool. Am Surg 82:259-65
Camp, Nicola J; Lin, Wei-Yu; Bigelow, Alex et al. (2016) Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Res 76:1916-25

Showing the most recent 10 out of 1049 publications